ライフサイエンスコーパス: radioimmunoconjugate

1 oinjection of 0.1 mg of panitumumab with the radioimmunoconjugate.

2 ted a high HER1-specific tumor uptake of the radioimmunoconjugate.

3 arly as 24 h after the administration of the radioimmunoconjugate.

4 cularly defined antibody-drug conjugates and radioimmunoconjugates.

5 have demonstrated the safety and efficacy of radioimmunoconjugates.

6 clonal anti-CD20 has impressive activity and radioimmunoconjugates.

7 nd prostate cancer patients who received the radioimmunoconjugate 111In-2IT-BAD-m170, 91% and 94% of

8 The radioimmunoconjugate, 67Cu-21T-BAT-Lym-1, has been shown

9 The approved anti-CD20 radioimmunoconjugates ((90)Y-ibritumomab tiuxetan or (13

10 The novel radioimmunoconjugate, 90Y-DOTA-peptide-chimeric L6 (ChL6

11 mg dependent on the specific activity of the radioimmunoconjugate and was infused at a rate of 0.5-1

12 purging mechanisms and nonmyeloablative and radioimmunoconjugated antibodies as alternate preparativ

13 Radioimmunoconjugates are associated with transient panc

14 Thereby, corresponding radioimmunoconjugates are formed in vivo and, consequent

15 This article reviews the development of radioimmunoconjugates as a new class of cancer therapeut

16 aims to potentiate the therapeutic action of radioimmunoconjugates at the tumor site and thus improve

17 conjugated anti-CD20 antibody therapy with a radioimmunoconjugate binding to a noncompeting antigen m

18 We have developed (111)In-labeled bispecific radioimmunoconjugates (bsRICs) that bind HER2 and EGFR o

19 Our objective was to construct bispecific radioimmunoconjugates (bsRICs) that recognize HER2 and H

20 ng agents allow formation of stable metallic radioimmunoconjugates but have been reported to be immun

21 cancer xenografts and compared to analogous radioimmunoconjugates employing the ubiquitous chelator

22 (177)Lu-RS7 is an effective radioimmunoconjugate for radioimmunotherapy.

23 ane-N,N',N",N"'-tetraacetic acid) is a novel radioimmunoconjugate for targeting radiation to cancer.

24 Drug Administration will approve one or more radioimmunoconjugates for clinical use.

25 been recently investigated for the design of radioimmunoconjugates for immuno-PET.

26 ntial for use in the design and synthesis of radioimmunoconjugates for immunoPET.

27 isting immunotherapies such as rituximab and radioimmunoconjugates has generated much data in the pas

28 sed bispecific antibodies, immunotoxins, and radioimmunoconjugates have been examined in preclinical

29 Metallic radioimmunoconjugates have promise for radioimmunoimagin

30 Two radioimmunoconjugates, ibritumomab tiuxetan (Zevalin) an

31 ts, with trials now seeking to incorporate a radioimmunoconjugate in various settings.

32 tic acid binds 67Cu tightly to form a stable radioimmunoconjugate in vivo.

33 nti-epithelial glycoprotein-1 MAb) furnished radioimmunoconjugates in good overall incorporations, wi

34 el of ovarian carcinoma after injection of a radioimmunoconjugate labeled with (211)At for TAT.

35 ed with increased effective half-life of the radioimmunoconjugate (P = .009).

36 effector type: immunotoxins (protein toxin), radioimmunoconjugates (radionuclide), and antibody drug

37 Progress in the clinical use of radioimmunoconjugates remains hindered by complexity of

38 ive monoclonal antibodies, immunotoxins, and radioimmunoconjugates (RICs) has stimulated considerable

39 Tumor-selective radioimmunoconjugates specific for embryonal tumors of c

40 Both radioimmunoconjugates specifically bound to HCT-15 cells

41 Radioimmunoconjugates targeting GD2 may have clinical ut

42 Interestingly, the radioimmunoconjugate that yielded the best tumor-to-norm

43 together, our findings establish the use of radioimmunoconjugates that target gammaH2AX as a noninva

44 or molecules are delivered as presynthesised radioimmunoconjugates, the pretargeting approach is a mu

45 jection of (111)In-hu3S193 and (86)Y-hu3S193 radioimmunoconjugates, the uptake of (111)In and (86)Y a

46 n anti-CD20 therapy enhances the efficacy of radioimmunoconjugate therapy.

47 hether to incorporate monoclonal antibody or radioimmunoconjugate therapy.

48 I as an adjunct to determine localization of radioimmunoconjugates to hematolymphoid tissues.

49 raise important questions concerning current radioimmunoconjugate treatment regimens and ways to impr

50 be given to fractionating or giving multiple radioimmunoconjugate treatments.

51 ere analyzed for retention and metabolism of radioimmunoconjugates using cellular-radioimmunoassays,

52 The radioimmunoconjugate was tested for immunoreactivity, in

53 The in vivo behavior of the resulting radioimmunoconjugates was investigated in mice bearing o

54 High uptake and good retention of the radioimmunoconjugate were observed at the surface of tum

55 Radioimmunoconjugates were retained in the peritoneal ca

56 standing the unique properties of this novel radioimmunoconjugate will facilitate its safe and effect

57 25)Ac, high technical requirement to prepare radioimmunoconjugate with very short half-life (T(1/2) =